Tools for SARS-CoV-2 Research
The 2019 novel coronavirus SARS-CoV-2 has caused an outbreak of the respiratory illness COVID-19 that started in Wuhan City, Hubei Province, China and has now spread throughout the world to many different countries. The World Health Organization (WHO) has declared a global health emergency to gather resources and remedy this threat.
To support SARS-CoV-2 research, we have listed the relevant products (research use only) offered by BioCat below.
This product listing is updated and extended regularly. If you cannot find the product you are looking for, please contact our scientific support team, who will be able to help you.
- Gene Synthesis Service
- Isolation of Virus RNA from Respiratory Specimens
- SARS-CoV-2 Detection by Real-Time RT-PCR
- SARS-CoV-2 NGS Panels for Targeted Sequencing
- SARS-CoV-2 Recombinant Proteins
- SARS-CoV-2 Antibodies
- SARS-CoV-2 IgM/IgG Antibody Detection using Lateral Flow Immunoassays
- SARS-CoV-2 Protein & Antibody Detection by ELISA
- SARS-CoV-2 IgM and IgG Antibody Detection using Peptide Microarrays
- SARS-CoV-2 Inhibitor Screening
- Blood Products from Convalescent COVID-19 Donors
- TargetMol Anti-COVID-19 Compound Libraries
- Antiviral Agents for SARS-CoV-2 (COVID-19) Research
- RayBio Inflammation Cytokine Arrays & ELISA Kits
- SARS-CoV-2 Spike Protein-Pseudotyped Lentivirus
Gene Synthesis Service
Our partner General Biosystems can synthesize genes of any length and complexity to suit your needs.
Send us your synthesis request
- Genes up to 15,000 bp in length
- 100% sequence accuracy guarantee
- Free codon optimization
- Free cloning into many standard vectors
- Short turnaround time
- Plasmid purification service
- Cost-saving mutagenesis service
- Gene fragment synthesis service
Isolation of Virus RNA from Respiratory Specimens
Accurate diagnosis of COVID-2019 infection is through the use of real-time RT-PCR assays for the in vitro qualitative detection of the virus in respiratory specimens and sera. To isolate the preserved RNA from these samples, high-quality Total RNA Purification Kits developed by our partners Bioline, BioVision, Epigentek and Norgen are offered.
|Total RNA Purification Kit for cultured animal cells, tissue samples, blood, plasma, serum, saliva, bacteria, yeast, fungi, plants and viruses||17200-NB||50 preps||344.00 €|
|Total RNA Purification Kit for cultured animal cells, tissue samples, blood, plasma, serum, saliva, bacteria, yeast, fungi, plants and viruses||37500-NB||100 preps||596.00 €|
|Total RNA Purification Kit for cultured animal cells, tissue samples, blood, plasma, serum, saliva, bacteria, yeast, fungi, plants and viruses - CE-marked (for IVD)||Dx17200-NB||50 preps||356.00 €|
|Total RNA Purification Kit (96-well column chromatography) for mammalian cells and tissue, blood, plasma / serum, bacteria, yeast, fungi, plants, and viruses||24370-NB||6 plates/ 576 preps||2340.00 €|
|Total RNA Purification Kit (96-well column chromatography, deep-well-format) for mammalian cells and tissue, blood, plasma / serum, bacteria, yeast, fungi, plants, and viruses||24350-NB||2 plates/ 192 preps||884.00 €|
|Total RNA Purification Kit (96-well column chromatography, deep-well-format) for mammalian cells and tissue, blood, plasma / serum, bacteria, yeast, fungi, plants, and viruses||24380-NB||6 plates/ 576 preps||2340.00 €|
|EpiQuik Viral RNA Isolation Fast Kit||P-9107-050-EP||50 rxns||238.00 €|
|EpiMag Viral RNA Isolation Kit||P-9108-050-EP||50 rxns||164.00 €|
|EpiMag 96-Well Viral RNA Extraction Kit (High Throughput)||P-9109-96-EP||96 rxns||337.00 €|
|Viral RNA Extraction Kit for Respiratory Specimens||K1462-50-BV||50 rxns||439.00 €|
|ISOLATE II RNA Micro Kit, 50 Preps||BIO-52075-BL||50 preps||380.00 €|
|ISOLATE II RNA Mini Kit, 50 Preps||BIO-52072-BL||50 preps||240.00 €|
For the safe collection, transport and preservation of respiratory samples, the Norgen Swab Collection and Total Nucleic Acid Preservation System and Norgen Saliva RNA Collection and Preservation Devices as well as the ABM Sample Collection and Viral Transport Solution are provided.
SARS-CoV-2 Detection by Real-Time RT-PCR
Real-Time RT-PCR technology is used for the specific identification and differentiation of 2019 Novel Coronavirus (SARS-CoV-2) in respiratory samples from patients with signs and symptoms of COVID-19 infection. RNA is extracted from respiratory specimens (suitable Total RNA Isolation Kits, see above), amplified by real-time RT-PCR and detected using fluorescent reporter dye probes specific for SARS-CoV-2.
Several real-time RT-PCR assays (research use only) developed by our partners ABM, BioVision, GeneCopoeia, LGC Biosearch, Norgen and RayBio are provided. The assays are designed for specifically detecting SARS-CoV-2 gene targets, such as ORF1ab or N (recommended by WHO and US CDC). For details, please see individual products below.
|COVID-19 TaqMan RT-PCR Kit (E/RdRP genes- Charite/Berlin protocol)||TM67240-NB||40 rxns||265.00 €|
|COVID-19 TaqMan RT-PCR Kit (E/RdRP genes- Charite/Berlin protocol)||TM67200-NB||500 rxns||3015.00 €|
|COVID-19 TaqMan RT-PCR Kit (E/RdRP genes- Charite/Berlin protocol) - CE-marked (for IVD)||DxTM67200-NB||500 rxns||3015.00 €|
|2019-nCoV TaqMan RT-PCR Kit (N1/N2/RnaseP- CDC protocol)||TM67100-NB||50 rxns||410.00 €|
|2019-nCoV TaqMan RT-PCR Kit (N1/N2/RnaseP- CDC protocol)||TM67120-NB||500 rxns||3015.00 €|
|2019-nCoV TaqMan RT-PCR Kit (N1/N2/RnaseP- CDC protocol) - CE-marked (for IVD)||DxTM67100-NB||50 rxns||410.00 €|
|2019-nCoV Primer & Probe Mixes||TM67101-NB||50 rxns||138.00 €|
|2019-nCoV RT-PCR Positive Control||PC67102-NB||50 ul||138.00 €|
|2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2||KIT-NCOV-PP1-1000-BS||1000 rxns||415.00 €|
|BlazeTaq Probe One-Step SARS- CoV-2 Detection Kit with ROX dye (20ul x 200rxns)||QP201-GC||200 rxns||967.00 €|
|BlazeTaq Probe One-Step SARS- CoV-2 Detection Kit with ROX dye (20ul x 1000rxns)||QP202-GC||1000 rxns||3350.00 €|
|BlazeTaq Probe One-Step SARS- CoV-2 Detection Kit without ROX dye (20ul x 200rxns)||QP203-GC||200 rxns||967.00 €|
|BlazeTaq Probe One-Step SARS- CoV-2 Detection Kit without ROX dye (20ul x 1000rxns)||QP204-GC||1000 rxns||3350.00 €|
|GenomeCoV19 Detection Kit, upgraded Version - CE-marked (for IVD)||G628.v2-ABM||100 rxns||475.00 €|
|GenomeCoV19 Detection Kit - CE-marked (for IVD)||G628-ABM||100 rxns||475.00 €|
|Coronavirus (SARS-CoV-2) Real Time RT-PCR Nucleic Acid Detection Kit||PCR-COV-RB||20 tests||525.00 €|
|COVID19 High Throughput Real Time RT-PCR Nucleic Acid Detection Kit||PCR-COVHT-RB||80 Tests||683.00 €|
|COVID-19 (SARS-CoV-2) Real Time RT-PCR 1-Step Nucleic Acid Detection Kit||PCR-COV-OS-RB||30 samples||695.00 €|
|Coronavirus Rapid RT-qPCR Detection Kit||K1461-100-BV||100 Reactions||597.00 €|
In addition, the COVID-19 Rapid Isothermal PCR Kit utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP), which amplifies SARS-CoV-2 RNA without the need for thermal cycling, is offered.
SARS-CoV-2 NGS Panels for Targeted Sequencing
The myBaits Expert Virus SARS-CoV-2 Panel is designed for NGS target enrichment of the whole genome of 2019 novel coronavirus (SARS-CoV-2) responsible for COVID-19 disease and is based on all full and partial genome sequences available in the NCBI database as of January 31, 2020. The design of the probes (biotinylated RNA “baits”) is compatible with enriching both long and short NGS library molecules (even from degraded targets).
- Convenient – Use the same NGS library preparation or protocol for shotgun sequencing
- Open Platform – Compatible with any NGS library platform, including long-read sequencing
- Complete Solution – Kits include all necessary reagents to perform enrichment of NGS libraries
The Swift Amplicon SARS-CoV-2 Panel offers a robust NGS workflow that provides optimal coverage and NGS data quality on Illumina sequencing platforms. This kit leverages patented multiplex PCR technology, enabling library construction from 1st-strand or 2nd-strand cDNA using tiled primer pairs to target the entire 29.9 kb viral genome with a single pool of multiplexed primer pairs.
- SARS-CoV-2 whole viral genome single-tube NGS assay
- 341 amplicons sized 116-255 bp (average 150 bp)
- 98% SARS-CoV-2 genome coverage (29,313 of 29,903 bases)
- 2 hours cDNA-to-library processing time
SARS-CoV-2 Recombinant Proteins
SARS-CoV-2 is an enveloped positive-strand RNA virus that consists of four structural proteins: spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein. The spike protein is the most important surface protein of coronavirus. It mediates the entry of SARS-CoV-2 into human respiratory epithelial cells by interacting with the cell surface receptor angiotensin-converting enzyme 2 (ACE2).
BioCat provides a large selection of recombinant proteins for SARS-CoV-2 research including nucleocapsid protein, spike protein and angiotensin-converting enzyme 2, see link below.
In response to the coronavirus COVID-19 pandemic, our partners BioVision, ProSci and RayBio have developed a comprehensive selection of antibodies including polyclonal, monoclonal and single domain antibodies for the detection of SARS-CoV-2 structural and non-structural proteins. Antibodies against SARS-CoV-2 nucleocapsid protein, envelope protein as well as spike protein and its subunits spike S1, spike S1 RBD (receptor binding domain), spike S2 and spike ECD (extracellular domain) are offered, see link below.
SARS-CoV-2 IgM/IgG Antibody Detection using Lateral Flow Immunoassays
Our partners ABM, BioVision, Epigentek and RayBio have developed colloidal gold-based lateral flow immunoassays for the fast detection of IgM or IgG antibodies specific for SARS-CoV-2 (COVID-19) proteins in human serum, plasma, whole blood or finger prick samples.
- Fast lateral flow device-based detection of IgM or IgG antibodies specific for SARS-CoV-2 proteins
- No sample preparation or instruments necessary
- Direct detection from plasma, serum, whole blood or fingertip blood
- Qualitative results within 10 minutes
SARS-CoV-2 Protein & Antibody Detection by ELISA
The RayBio COVID-19 N-Protein and S-Protein ELISA kits are designed for the quantitative detection of SARS-CoV-2 nucleocapsid and spike protein, respectively, in serum and cell culture supernatants.
For the measurement of human antibodies against SARS-CoV-2 N protein or SARS-CoV-2 S-Protein in human serum or plasma, we offer the following indirect ELISAs
- RayBio COVID-19 N-Protein Human IgG Quantitative ELISA
- RayBio COVID-19 N-Protein Human IgM ELISA
- RayBio COVID-19 N-Protein Human IgA ELISA
- RayBio COVID-19 S-Protein (S1RBD) Human IgG Quantitative ELISA
- RayBio COVID-19 S-Protein (S1RBD) Human IgM ELISA
- RayBio COVID-19 S-Protein (S1RBD) Human IgA ELISA
- Epigentek SeroFlash SARS-CoV-2 IgG/IgM ELISA Fast Kit (S-Protein)
SARS-CoV-2 IgM and IgG Antibody Detection using Peptide Microarrays
In light of the recent coronavirus disease (COVID-19) outbreak, our partners PEPperPRINT and RayBio have developed peptide microarrays based on the SARS-CoV-2 (2019-nCoV) viral genome.
The PEPperCHIP SARS-CoV-2 Proteome Microarray enables researchers to serologically screen 4,883 individual peptides spanning the entire SARS-CoV-2 proteome. It can be used to detect IgG and IgM antibody responses on the epitope level in patient sera for in vitro diagnostic test or vaccine development.
The RayBio COVID-19 Spike Protein Array is designed for the semi-quantitative detection of IgM and IgG antibodies specific for the SARS-CoV-2 (COVID-19) spike (S) protein in serum or plasma.
The PEPperCHIP Pan-Corona Spike Protein Microarray is designed for the serological screening of all seven human coronavirus spike proteins in one assay. It can be used to analyze antibody cross-reactivity and specificity against multiple human coronavirus spike proteins, and identify and characterize IgA, IgG or IgM coronavirus spike protein epitopes with amino-acid precision. The chip contains spike proteins of SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-HKU1, HCoV-NL63 and HCoV-229E translated into 4,564 individual peptides.
SARS-CoV-2 Inhibitor Screening
With no evidence yet for effective COVID-19 treatments, there is an urgent need for the development of SARS-CoV-2 inhibitors, including vaccines, therapeutic antibodies and small molecular compounds.
The SARS-CoV-2 inhibitor screening and spike/ACE2 binding assay kits are based on the interaction between ACE2 protein and SARS-CoV-2 spike protein RBD. ELISA-like kits for the detection of SARS-CoV-2-targeted furin activity are also available. These assays are designed to facilitate the identiﬁcation and characterization of SARS-CoV-2 inhibitors.
Blood Products from Convalescent COVID-19 Donors
Convalescent plasma therapy is an experimental treatment being used for people with severe COVID-19. To support the related research activities, our partner ZenBio can provide blood products like plasma or Peripheral Blood Mononuclear Cells (PBMCs) collected from patients who have recovered from COVID-19 infection. The evidence of COVID-19 has been documented by a laboratory test, either a diagnostic test (e.g., nasopharyngeal swab) at the time of illness or a positive serological test for SARS-CoV-2 antibodies after recovery.
TargetMol Anti-COVID-19 Compound Libraries
In order to respond to the outbreak of pneumonia caused by the novel coronavirus SARS-CoV-2 (2019-nCoV), researchers are working hard to identify drug candidates that can be used for clinical therapy for patients with SARS-CoV-2 (2019-nCoV) infected pneumonia by screening compound libraries. Our partner TargetMol, a drug screening expert, has generated a compound library by carefully selecting 2448 compounds that have been demonstrated to have anti-coronavirus activity including broad-spectrum antiviral agents like Remdesivir, Lopinavir/Ritonavir, Chloroquine diphosphate (combination use with Remdesivir), Polydatin (bind with Mpro), etc., see below. This library will be updated in response to the latest research progress.
- Unique collection of 2448 compounds with anti-coronavirus activity, part of them are broad-spectrum antiviral agents
- Detailed compound information including structure, target and biological activity
- Validated by NMR and HPLC to ensure high purity and quality
Anti-COVID-19 Compound Libraries developed applying Computer-Aided Drug Design (CADD)
The Anti-COVID-19 Compound Library (CADD), 364 compounds, comprises compounds having the potential of anti-SARS-CoV-2 activity. It can be used for high-throughput screening and high-content screening. Targets include viral papain like protease (PLpro), main protease (3CLpro, also named 3-chymotrypsin-like protease), RNA-dependent RNA polymerase (RdRp), nsp16 (2′-O-methyltransferase, helicase), RBD of spike as well as human ACE2.
In addition, TargetMol has developed Anti-COVID-19 Compound Libraries (CADD) targeting individual SARS-CoV-2 key proteins like spike-RBD, ACE2, Mpro (3CLpro), PLpro, nsp15, nsp16, X domain and RdRp (nsp12) .
Antiviral Agents for SARS-CoV-2 (COVID-19) Research
Based on virtual screening results and combined with the recent clinical reports, our partner TargetMol has obtained some valuable potential drugs for SARS-CoV-2, which can reduce the drug development cycle by using drug relocation strategy. Promising antiviral agents include Darunavir, Remdesivir, Camostat mesilate, Baricitinib, Favipiravir, Ribavirin, Chloroquine diphosphate and Nitazoxanide.
RayBio Inflammation Cytokine Arrays & ELISA Kits
During infection of the coronavirus SARS-CoV-2, high levels of inflammatory cytokines have been reported. These cytokines include interferons, interleukins, chemokines, colony-stimulating factors, and tumor necrosis factors and contribute to the symptoms of coronavirus infection: redness, swelling/edema, fever, and pain. Overproduction of pro-inflammatory cytokines can result in a “cytokine storm,” during which inflammation spreads throughout the body via the circulation. One common consequence of a cytokine storm is acute lung injury, which can progress to a more severe form called acute respiratory distress syndrome.
Using quantitative inflammation antibody arrays developed by our partner RayBio, the dynamic relationship of cytokines during inflammation can be measured.
- Quantibody Human Inflammation Array 1 (10 antibodies)
- Quantibody Human Inflammation Array 3 (40 antibodies)
- Quantibody Human Cytokine TH1/TH2 Array I (10 antibodies)
Specific inflammatory proteins can be measured with RayBio ELISA kits. Below are some of the featured ELISA kits to help study COVID-19 inflammation:
- Human IL-6 ELISA
- Human IL-10 ELISA
- Human IFN-γ ELISA
- Human M-CSF ELISA
- Human MIP-1α ELISA
- Human TGFβ1 ELISA
- Human TIMP-1 ELISA
- Human TNFα ELISA
SARS-CoV-2 Spike Protein-Pseudotyped Lentivirus
SARS-CoV-2 Spike protein-pseudotyped lentivirus products generate a specially-packaged variant of standard lentivirus, whereby the commonly used vesicular stomatitis G (VSV-G) envelope glycoprotein is replaced by the Spike (S) protein or the Spike D614G mutant from SARS-CoV-2, the virus responsible for the COVID-19 pandemic.
The resulting lentiviral particles can be used in vitro to infect cultured cells expressing ACE2, the receptor for SARS-CoV-2 in multiple tissue types, or in vivo in animal models.
SARS-CoV-2 (2019-nCoV) Background
There are four coronavirus genera [ii]: alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus. SARS-CoV-2 (2019-nCoV) belongs to the Betacoronavirus genus originating from bats. Betacoronaviruses can infect mammals, are zoonotic pathogens, and can cause severe respiratory disease in humans. Other viruses in this family are SARS coronavirus and MERS coronavirus. SARS-CoV-2 (2019-nCoV) has approximately 79% sequence identity to SARS-CoV and 50% to MERS-CoV [iii]. In addition, homology modeling shows SARS-CoV-2 (2019-nCoV) has a similar receptor-binding domain structure as SARS-CoV which suggests SARS-CoV-2 (2019-nCoV) may use ACE2 as a receptor in humans for infection.
SARS-CoV-2 (2019-nCoV) Structure
The structure [iv] of SARS-CoV-2 (2019-nCoV) consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleocapsid protein (N) and RNA as seen in the figure.
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 https://doi.org/10.1038/s41586-020-2012-7
[ii] Fan, Y.; Zhao, K.; Shi, Z.-L.; Zhou, P. Bat Coronaviruses in China. Viruses 2019, 11, 210. https://doi.org/10.3390/v11030210
[iii] Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. Published online January 29, 2020. https://doi.org/10.1016/S0140-6736(20)30251-8
[iv] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1